Galena Biopharma Inc (GALE) reported quarterly earnings results on Tuesday, Aug-9-2016. The company said it had a profit of $0.05 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.11. Analysts had a consensus of $-0.06. During the same quarter in the previous year, the company posted $-0.10 EPS.
Many Wall Street Analysts have commented on Galena Biopharma Inc. Shares were Reiterated by FBR Capital on Jul 22, 2016 to “Outperform” and Lowered the Price Target to $ 2 from a previous price target of $5 .Shares were Reiterated by Maxim Group on Jul 11, 2016 to “Buy” and Lowered the Price Target to $ 2 from a previous price target of $4 .Galena Biopharma Inc was Downgraded by Raymond James to ” Mkt Perform” on Jun 29, 2016.
Galena Biopharma Inc opened for trading at $0.486 and hit $0.51 on the upside on Monday, eventually ending the session at $0.486, with a gain of 1.17% or 0.0056 points. The heightened volatility saw the trading volume jump to 38,83,097 shares. Company has a market cap of $88 M.
In a different news, on Jun 7, 2016, Ryan Dunlap (Former Chief Financial Officer) sold 126,875 shares at $2.18 per share price.
Galena Biopharma Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets including immunotherapy program led by its lead product NeuVax (nelipepimut-S) which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.